文献速递其他结缔组织病

抗MDA5抗体阳性炎症性肌病患者的临床特征及抗体滴度变化

Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究纳入2008-2016年新诊断的105例PM/DM患者,用ELISA检测抗MDA5抗体,比较抗体阳性与阴性者的临床特征,并观察治疗前后抗体滴度变化。结果显示抗体阳性者皮炎、临床无肌病性DM、间质性肺病及快速进展型间质性肺病更常见,血清铁蛋白更高,肌酸激酶和醛缩酶更低,ANA(≥1:160)及抗胞质型ANA荧光阳性更少。治疗后抗体滴度在幸存者中下降显著少于非幸存者,但治疗2个月时两组下降率无显著差异。

要点

  • 抗MDA5抗体阳性者皮炎、临床无肌病性DM、间质性肺病及快速进展型间质性肺病更常见。
  • 抗体阳性者血清铁蛋白更高,肌酸激酶和醛缩酶更低,ANA(≥1:160)及抗胞质型ANA阳性更少。
  • 治疗后抗体滴度在幸存者中下降显著少于非幸存者,但2个月时下降率无显著差异。

核心结论

  • 大多数患者治疗后抗MDA5抗体滴度初始下降,包括致命病例,提示该指标不一定是有用的治疗标志物。

研究设计与样本

  • 研究纳入2008-2016年本院新诊断的105例PM/DM患者,用MESACUP抗MDA5检测试剂盒以ELISA法在诊断时及治疗后检测血清抗MDA5抗体水平。

主要发现

  • 与抗MDA5抗体阴性患者相比,抗体阳性者皮炎、临床无肌病性DM、间质性肺病和快速进展型间质性肺病更频繁。
  • 抗体阳性者血清铁蛋白显著更高,肌酸激酶和醛缩酶显著更低,ANA(≥1:160)及抗胞质型ANA荧光阳性显著更少。
  • 两例患者在发病前检测抗体:一例在2年前呈低滴度阳性,两例在发病时滴度均升高。
  • 治疗后抗MDA5抗体滴度在幸存者中下降显著少于非幸存者,但治疗2个月时两组下降率比较无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the clinical characteristics of patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive inflammatory myositis, and the change in anti-MDA5 antibody titres before and after onset. METHOD: For 105 PM/DM patients, newly diagnosed in our hospital within the period 2008-2016, serum anti-MDA5 antibody levels were measured at diagnosis and after treatment by ELISA using the MESACUP anti-MDA5 test. The relationships between anti-MDA5 antibody levels and clinical manifestations, laboratory data, and mortality were examined. RESULT: Compared with patients who were anti-MDA5 antibody negative, those who were antibody positive demonstrated more frequent dermatitis, clinically amyopathic DM, interstitial lung disease and rapid-progressive interstitial lung disease, as well as significantly higher serum ferritin, significantly lower creatine kinase and aldolase, and significantly less frequent ANA (⩾1:160) and anti-cytoplasmic pattern of ANA staining positivity. Anti-MDA5 antibody titres were examined before disease onset in two patients; one showed antibody positivity with low titres 2 years earlier, while both exhibited increased titres at onset. Anti-MDA5 antibody titres declined significantly less in survivors than in non-survivors after treatment; however, there was no significant difference between the two groups when the rate was compared at 2 months after treatment. CONCLUSION: An initial decrease in anti-MDA5 antibody titre after commencement of treatment was observed in most of the patients, including in fatal cases, suggesting that this may not necessarily be a useful marker for treatment of patients with DM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Abe Y, Matsushita M, Tada K, et al. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017. PMID: 28499006. doi:10.1093/rheumatology/kex188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。